https://www.selleckchem.com/products/azd9291.html
Successful neoadjuvant chemotherapy (NACT) could improve the surgical resection rate and radical curability of patients with cervical cancer, but only a subset of patients benefits. Therefore, identifying predictive biomarkers are urgently needed. The aim of this study was to evaluate the predictive value of CD34 and Bcl-2 in the NACT effectiveness of cervical cancer. Sixty-seven patients with locally advanced cervical cancer (FIGO stages IB3, IIA2 or II were classified into two groups based on effective (n = 48) and ineffective (n =
Like
Comment
Share
